InNexus Biotechnology Announces a Significant Expansion to its Intellectual Property and Product Development Strategy
June 02 2005 - 10:30AM
PR Newswire (US)
InNexus Biotechnology Announces a Significant Expansion to its
Intellectual Property and Product Development Strategy TSX.V: IXS
OTC BB: IXSBF VANCOUVER, June 2 /PRNewswire-FirstCall/ -- InNexus
Biotechnology, Inc. is pleased to announce an expansion to its
Intellectual Property portfolio. InNexus has filed additional
claims and support for its SuperAntibodies(TM), capable of creating
high therapeutic potency through binding and cross-linking of
target antigens. InNexus has been issued patents and has other
applications pending and in review for worldwide protection on its
method for creating SuperAntibodies(TM). The current filing is an
expansion of claims for specific SuperAntibody products, primarily
derived from existing FDA-approved monoclonal antibodies.
SuperAntibody Technology can be used to create second-generation,
improved versions of marketed antibodies thereby expanding market
indications, revenues and prolonging the patent life. The patent
filing allows InNexus to work with companies desiring to bring next
generation products to market or companies wanting to develop
competitive products to those already on the market. To support
this business strategy, InNexus has produced SuperAntibody versions
of existing, FDA-approved monoclonal antibody products,
demonstrated their therapeutic superiority to the marketed products
and used the information to file specific product and indication
claims. With this information and specific patent claims, InNexus
believes it can expand its financial support and develop further
collaborations for product development. Dr. Charles Morgan,
President & CEO of InNexus stated, "This is an important,
value-adding component to SuperAntibody Technology because it
allows faster entry into the marketplace with SuperAntibodies into
proven high value markets; for which revenues can be projected with
reasonable confidence". About InNexus InNexus is an innovative
antibody-driven drug development company that has developed two
technology platforms, SuperAntibody(TM) and TransMAbs(TM), which
improve the potency of existing antibody products while opening new
markets and disease applications. Both platforms utilize unique,
novel and patented methods and technologies of InNexus. InNexus is
headquartered in British Columbia, Canada and has its own in-house
developmental facilities. These development facilities provide
validation of protein and peptide discoveries, enabling InNexus
(and its strategic partners) to advance novel drug therapeutics and
diagnostics. To learn more about InNexus please visit
http://www.innexusbiotech.com/. This news release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements are not
historical facts and are subject to risks and uncertainties which
could cause actual results and the timing of certain events to
differ materially from those set forth in or implied herein
including, without limitation, risks associated with clinical
development, regulatory approvals, product commercialization,
intellectual property claims litigation and other risks associated
with the Company's proposed activities. On behalf of the Board of
Directors of InNexus Biotechnology, Inc. "ALTON C. MORGAN" Dr. A.
Charles Morgan President & CEO Investor Relations: Toll-free:
1-866-990-8382 or 1-888-271-0788 The TSX Venture Exchange does not
accept responsibility for the adequacy or accuracy of this release.
DATASOURCE: InNexus Biotechnology, Inc. CONTACT: Investor
Relations: Toll-free: 1-866-990-8382 or 1-888-271-0788,
Copyright